


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SINO BIOPHARMACEUTICAL LIMITED**  
**中國生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

*Website: [www.sinobiopharm.com](http://www.sinobiopharm.com)*

**(Stock code: 1177)**

**VOLUNTARY ANNOUNCEMENT**  
**SHARE PURCHASE PURSUANT TO**  
**RESTRICTED SHARE AWARD SCHEME**

Reference is made to the announcement of Sino Biopharmaceutical Limited (the “**Company**”) dated 5 January 2018 (the “**Announcement**”) in relation to the adoption of the restricted share award scheme (the “**Scheme**”) by the Company. Unless otherwise defined herein, capitalised terms used in this announcement have the same meanings as defined in the Announcement.

On 28 April 2022, the Trustee further purchased 8,500,000 Shares from the market to hold on trust for the benefit of the Selected Participants pursuant to the terms and conditions of the Scheme Rules. Details of the Shares purchased on 28 April 2022 and held by the Trustee on trust are as follows:

|  |                              |
|--|------------------------------|
| Total number of Shares purchased:  | 8,500,000 Shares             |
| Percentage of the Shares purchased<br>to the existing total number of Shares in issue: | Approximately 0.0451%        |
| Average consideration per Share:   | Approximately HK\$4.0499     |
| Total consideration of Shares purchased:   | Approximately HK\$34,424,150 |
| Balance of Shares held by the Trustee:   | 205,241,500 Shares           |

Up to the date of this announcement, no Shares have been awarded to any Selected Participants pursuant to the Scheme. The Board will from time to time review and determine at its absolute discretion such number of Shares to be awarded to the Selected Participants with such vesting conditions as it may deem appropriate and the number of Shares to be further purchased from the market under the Scheme.

By order of the Board  
**Sino Biopharmaceutical Limited**  
**Tse, Theresa Y Y**  
*Chairwoman*

Hong Kong, 28 April 2022

*As at the date of this announcement, the Board of the Company comprises nine executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.*